Doxycycline (hydrochloride)
CAT:
804-HY-N0565A-01
Size:
10 mM / 1 mL
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Doxycycline (hydrochloride)
- CAS Number: 10592-13-9
- UNSPSC Description: Doxycycline hydrochloride, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor[1]. Doxycycline hydrochloride shows antibacterial activity and anti-cancer cell proliferation activity[1][2][3][4][5].
- Target Antigen: Antibiotic; Bacterial; MMP; Parasite
- Type: Reference compound
- Related Pathways: Anti-infection;Metabolic Enzyme/Protease
- Applications: COVID-19-immunoregulation
- Field of Research: Cancer; Infection
- Assay Protocol: https://www.medchemexpress.com/doxycycline-hydrochloride.html
- Purity: 99.99
- Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
- Smiles: O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])[C@@H](O)[C@]3([H])[C@@H](C)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N.Cl
- Molecular Weight: 480.90
- References & Citations: [1]Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7.|[2]Eusebio Manchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534(7609):647-51.|[3]Anna-Luisa Luger, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5):1504.|[4]Ethan Ahler, et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8(5):e64561.|[5]Le Zhang, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745.|[6]Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93(2):167-73.|[7]Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17(11):1857-67.|[8]Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8.Cancer Lett. 2016 Jun 28;376(1):188-96.|Cell Death Differ. 2019 Nov;26(11):2400-2415. |Cell Rep. 2024 Aug 22;43(9):114662.|Cell. 2023 Feb 2;186(3):591-606.e23.|Sci Adv. 2024 Apr 17;10(16):eadi1782|ACS Infect Dis. 2024 Apr 12;10(4):1327-1338.|Acta Pharmacol Sin. 2024 Aug 26.|Adv Sci (Weinh). 2021 Mar 15;8(10):2004344.|Ann Lab Med. 2021 May 1;41(3):293-301.|Biochem Biophys Res Commun. 30 July 2022.|Biomed Pharmacother. 2023 Jun 8;164:114998.|bioRxiv. 2023 Jun 14.|bioRxiv. 2023 Mar 31.|bioRxiv. 2024 July 05.|Cancer Biol Ther. 2022 Dec 31;23(1):328-335.|Cancer Res. 2023 Jul 18;CAN-23-0015.|Cell Commun Signal. 2022 Apr 12;20(1):52.|Cell Death Differ. 2023 Jun 15.|Cell Death Dis. 2020 May 7;11(5):331.|Cell Death Dis. 2022 Feb 10;13(2):138.|Cell Prolif. 2023 Aug 17;e13534.|Cell Rep. 2024 Jul 3;43(7):114431.|Clin Exp Pharmacol Physiol. 2023 Apr 22.|Drug Resist Updat. 2024 Jun 24:76:101112.|Emerg Microbes Infect. 2024 Dec;13(1):2321981.|FASEB J. 2020 Dec;34(12):16716-16735.|FASEB J. 2024 Apr 30;38(8):e23628.|Front Cell Infect Microbiol. 28 April 2021.|Heliyon. 2024 May 30.|Int Immunopharmacol. 2024 Jun 24:138:112518.|Int J Mol Med. 2020 Apr;45(4):1187-1194.|iScience. 2023 Mar.|J Cell Mol Med. 2024 Sep;28(17):e70053.|J Clin Invest. 2024 Jan 18:e171995.|J Med Virol. 2024 May;96(5):e29634.|J Transl Med. 2024 Oct 10;22(1):923.|J Virol. 2024 Aug 30:e0133524.|Katedra farmakologie a toxikologie. 2020 Jul.|Mol Cancer. 2020 Mar 30;19(1):68.|Mol Oncol. 2024 May 22.|Molecules. 2023 Jul 26, 28(15), 5668.|Nat Commun. 2024 Apr 6;15(1):2989.|Nat Genet. 2024 Feb;56(2):294-305.|Nat Microbiol. 2023 Mar;8(3):410-423.|NPJ Parkinsons Dis. 2022 Aug 6;8(1):100.|Oncogene. 2023 Dec 15.|Oncogene. 2024 Oct 23.|Phytomedicine. 2024 Aug 22:134:155958.|Redox Biol. 2023 Mar 21;62:102686.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2023 Jul 11.|Research Square Preprint. 2024 Apr 8.|Research Square Preprint. 2024 Jan 23.|Sci Adv. 2022 Jan 28;8(4):eabl5220.|Stem Cell Res Ther. 2024 Oct 8;15(1):350.|Theranostics. 2022 Mar 28;12(7):3131-3149.|Vet Microbiol. 2024 May, 292, 110046.|Virol Sin. 2022 May 12;S1995-820X(22)00081-5.|Water Res. 2023 May 21, 120110.|Adv Sci (Weinh). 2022 Jun 2;e2104823.|Adv Sci (Weinh). 2024 Oct 8:e2404756.|Biochem Biophys Res Commun. 6 August 2022.|bioRxiv. 2019 Apr.|bioRxiv. 2024 Jan 23.|Cancer Commun (Lond). 2023 Dec 28.|Cancer Res Commun. 2024 Jul 1.|Cell Death Dis. 2017 Mar 23;8(3):e2702.|Cell Death Dis. 2021 Apr 20;12(5):413.|Cell Rep. 2021 Jun 8;35(10):109225.|Cell Rep. 2021 Sep 21;36(12):109739.|Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8.|Elife. 2021 Oct 27;10:e65759.|Food Funct. 16th November 2021.|Institute of Pharmacology and Toxicology University of Zürich. 2019 Nov.|J Biol Chem. 2022 Aug 12;102374.|J Biol Chem. 2023 Mar 17;104621.|J Genet Genomics. 2020 Nov 20;47(11):705-712.|Mol Cancer. 2020 Sep 9;19(1):139.|Nat Commun. 2023 Dec 20;14(1):8461.|Nucleic Acids Res. 2024 Aug 21:gkae707.|Patent. US11576860B2.|Patent. US20190365645A1.|Patent. US20190366064A1.|Patent. US 2019/0365645 A1.|Research Square Preprint. 2024 Dec 04.|Research Square Print. 2022 May.|Research Square Print. 2023 Mar 1.|STAR Protoc. 2021 Nov 5;2(4):100881.|STAR Protoc. 2021, 100548.|STAR Protoc. 2022 Apr 13;3(2):101296.|STAR Protoc. 2023 Feb 3;4(1):102092.|Theranostics. 2022 Jan 1;12(3):1187-1203.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: Launched